Product NewsQuanterix granted Breakthrough Device designation from U.S. FDA for NfL test for multiple sclerosis
Product NewsQuanterix granted Breakthrough Device designation from U.S. FDA for blood-based pTau-181 assay for Alzheimer’s Disease
Industry NewsQuanterix’ Simoa technology powers largest and most diverse global investigation of plasma neurofilament light’s role in dementia diagnosis
Product NewsQuanterix Launches High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection
Product NewsQuanterix Announces Commercial Availability of its Simoa Single Molecule Array Technology
